Company intelligence / Profile preview

ARC Therapies

Shinjuku, Tokyo Prefecture, Japanarctherapies.inc ↗

Ownership: Private
Development stage: Preclinical

Overview

ARC Therapies has discovered the YB328 bacterial strain linked to enhanced responses to immune checkpoint inhibitors in cancer patients. Initial murine model studies suggest potent anti-tumor immune activation; the company is advancing ARC0812 toward preclinical and human clinical trials, with studies ongoing to evaluate efficacy and administration methods.

Therapeutic areas: Oncology
Modalities: Live biotherapeutic product therapyMicrobial therapyImmune adjuvant (as a functional class)
Industry: Biotech

Drug pipeline

2 assets

ARC0812

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

National Cancer Center Japan (originating research/facility)collaborating with lead scientists from NCC

Beyond the preview

Go deeper on ARC Therapies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARC Therapies.

Explore the full profile